This content is from: United States

US tax reform incentivises IP strategy considerations

The US is increasingly becoming attractive again to IP-rich companies, especially large US pharmaceuticals and technology multinationals. Deductions from foreign-derived income attributable to intangibles (FDII) serve as a carrot, but other provisions in the tax code may yet impact the cost of relocating assets.

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an ITR subscriber? Log in here

Instant access to all of our content. Membership Options | 30 Day Trial